Graft Versus Host Disease Pipeline Comparative Analysis Review H2 2015

1. Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 23-Sep-2015 No. of pages: 337 Single User License: US $2000 Browse more Reports on Pharmaceuticals at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

2. Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

3. Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: AbbVie Inc., AbGenomics International, Inc., Actelion Ltd, Adienne Pharma & Biotech, Alexion Pharmaceuticals, Inc., Apceth GmbH & Co. KG, Athersys, Inc., Bellicum Pharmaceuticals, Inc., Bio-Cancer Treatment International Limited, Biogen, Inc., Bristol-Myers Squibb Company, Caladrius Biosciences, Inc., Cell2B S.A., CytoDyn Inc., Dr. Falk Pharma GmbH, Enlivex Therapeutics Ltd, Escape Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Generon (Shanghai) Corporation Ltd. And more… Drugs Profile Discussed in this Research: abatacept, AbGn-168H, aldesleukin, Alecmestencel-L, Alpha-1 Antitrypsin, alpha-1 proteinase inhibitor (human), ALXN-1007, anti-thymocyte globulin (rabbit), Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD, Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease, ApoCell, ATIR-101, BCT-100, begelomab, Biologics for Graft Versus Host Disease, bortezomib, BPX-501, brentuximabvedotin, budesonide, cannabidiol, Cell Therapy for Autoimmune Diseases and GVHD, Cell Therapy for Graft Versus Host DiseaseCell Therapy for Graft Versus Host Disease and Multiple Myeloma, cenicrivirocmesylate, CLBS-03, CRCBT-080004, cyclosporine IR + cyclosporine CR, CYP-001 and more… ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

4. Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015 Scope For Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD) • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Graft Versus Host Disease (GVHD) and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Graft Versus Host Disease (GVHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

5. Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD) • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

6. Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441